Zeteo Biomedical LLC
Zeteo Biomedical is a leading biomedical device technology company dedicated to providing patient-centric drug and biologic delivery systems. They develop innovative delivery device technology and provide technical services supporting the development and commercialization of drug/device combination products across various routes of administration including intranasal, ophthalmic, nose-to-brain, sublingual, buccal, otic, and animal care. Their mission is to create safe, simple-to-use products that protect the quality of life, with a strong commitment to quality, sustainability, and rapid deployment of medical countermeasures.
Industries
Nr. of Employees
small (1-50)
Zeteo Biomedical LLC
PO Box 342216, Austin, Texas 78734 USA
Patents
Products
Multi-dose reloadable nasal powder delivery device (active aerosolization)
Cartridge-reloadable handheld nasal powder device with on-board storage for multiple unit-dose cartridges, removable nasal tip for cleaning, and active aerosolization for metered powder dosing.
Single-use disposable nasal powder delivery device (pre-loaded)
Single-dose disposable nasal powder device pre-loaded with a unit dose for rapid-response, rescue or vaccination use; orientation independent and intended for self- or caregiver-administration.
Mono-dose reloadable nasal liquid dispenser
Precision metered liquid nasal dispenser offering mono-dose reloadable cartridges with on-board multi-dose storage options, designed for self- or caregiver-administration and rapid systemic or nose-to-brain delivery.
Multi-dose reloadable ophthalmic dispenser with unit-dose aseptic packaging
Compact multi-dose ophthalmic dispenser using reloadable cartridges of aseptically packaged unit doses, calibrated for micro-volume ophthalmic dosing (approx. 5–26 µL) with an automatic dose counter and sterility-maintaining single-use dispensing channels.
Unit-dose primary container platform (WIP-capable)
Primary container platform (unit-dose blisters) designed to be filled, stored in intermediate WIP state, and later integrated with dispenser systems to improve storage density and distribution logistics.
Multi-dose reloadable nasal powder delivery device (active aerosolization)
Cartridge-reloadable handheld nasal powder device with on-board storage for multiple unit-dose cartridges, removable nasal tip for cleaning, and active aerosolization for metered powder dosing.
Single-use disposable nasal powder delivery device (pre-loaded)
Single-dose disposable nasal powder device pre-loaded with a unit dose for rapid-response, rescue or vaccination use; orientation independent and intended for self- or caregiver-administration.
Mono-dose reloadable nasal liquid dispenser
Precision metered liquid nasal dispenser offering mono-dose reloadable cartridges with on-board multi-dose storage options, designed for self- or caregiver-administration and rapid systemic or nose-to-brain delivery.
Multi-dose reloadable ophthalmic dispenser with unit-dose aseptic packaging
Compact multi-dose ophthalmic dispenser using reloadable cartridges of aseptically packaged unit doses, calibrated for micro-volume ophthalmic dosing (approx. 5–26 µL) with an automatic dose counter and sterility-maintaining single-use dispensing channels.
Unit-dose primary container platform (WIP-capable)
Primary container platform (unit-dose blisters) designed to be filled, stored in intermediate WIP state, and later integrated with dispenser systems to improve storage density and distribution logistics.
Services
Characterization services including laser diffraction for droplet/particle size, high-speed video plume morphology, aerodynamic deposition testing (cascade impactor, nasal cast), delivered dose uniformity and emitted dose measurements, device actuation force and fluidic properties analysis.
Prototype configuration and supply, device and primary container optimization, analytical testing, process engineering for fill processes, and supply for pre-clinical and clinical studies including regulatory documentation support (e.g., DMF).
Commercial technology transfer, commercial scale-up, DMF/quality documentation assistance, commercial supply arrangements, capital equipment supply and siting, and technology licensing to support market deployment.
Characterization services including laser diffraction for droplet/particle size, high-speed video plume morphology, aerodynamic deposition testing (cascade impactor, nasal cast), delivered dose uniformity and emitted dose measurements, device actuation force and fluidic properties analysis.
Prototype configuration and supply, device and primary container optimization, analytical testing, process engineering for fill processes, and supply for pre-clinical and clinical studies including regulatory documentation support (e.g., DMF).
Commercial technology transfer, commercial scale-up, DMF/quality documentation assistance, commercial supply arrangements, capital equipment supply and siting, and technology licensing to support market deployment.
Expertise Areas
- Drug/device combination product development
- Intranasal and nose-to-brain delivery
- Ophthalmic drug delivery
- Powder and reconstituted powder formulation delivery
Key Technologies
- Form-fill-seal unit-dose blister packaging
- Active powder aerosolization
- Precision metered-dose mechanical dispensers
- Removable engineered nasal tips (species-specific)
News & Updates
The City of Cedar Park announced the relocation of Zeteo Biomedical, highlighting its commitment to the life sciences industry.
Zeteo Biomedical joins the U.S. Government’s RRPV, offering scalable solutions for rapid distribution of vaccines and medical countermeasures.
Zeteo announced the availability of the OrionMRQ™ nasal drug and vaccine delivery system, designed for precise, metered-unit delivery.
Zeteo Biomedical announced the launch of its CygnusMR™ and CygnusSDX™ delivery devices for nasal delivery of dry powder drugs and biologics.
Timothy Sullivan, CEO of Zeteo Biomedical, presented technology and future vision for protecting populations against pandemic threats.
Zeteo received a US patent for its oral delivery device and methods for vaccines and pharmaceuticals.
The City of Cedar Park announced the relocation of Zeteo Biomedical, highlighting its commitment to the life sciences industry.
Zeteo Biomedical joins the U.S. Government’s RRPV, offering scalable solutions for rapid distribution of vaccines and medical countermeasures.
Zeteo announced the availability of the OrionMRQ™ nasal drug and vaccine delivery system, designed for precise, metered-unit delivery.
Zeteo Biomedical announced the launch of its CygnusMR™ and CygnusSDX™ delivery devices for nasal delivery of dry powder drugs and biologics.
Timothy Sullivan, CEO of Zeteo Biomedical, presented technology and future vision for protecting populations against pandemic threats.
Zeteo received a US patent for its oral delivery device and methods for vaccines and pharmaceuticals.